Agilent Flow Cytometer Receives Drug Discovery Product Award

Agilent Technologies' NovoCyte Opteon spectral flow cytometer has been recognized by SelectScience with the 'Best New Drug Discovery & Development Product of 2024' award in the Scientist’s Choice Awards. The award highlights advancements in tools used for pharmaceutical research and development.

The instrument, launched in May 2024, features up to five lasers and 73 detectors. Agilent states its optical design and electronics enable high-resolution and sensitive data acquisition, assisting researchers in analyzing cellular processes more effectively.

The company notes that the flow cytometer's wide dynamic range for fluorescence detection and particle size measurement, along with onboard temperature control and sensor circuitry, are designed to ensure consistent and reliable data. Agilent also emphasizes that the instrument's software makes spectral flow cytometry more accessible to researchers.

The recognition follows a selection process involving input from the scientific community. Agilent Technologies continues to focus on providing technologies that support scientific research and therapeutic development.